CFMS BUY/LONG NOW READY! 0.8836 to potentially 3.900 by End 2022TICKER CODE : CFMS
Company Name: CONFORMIS INC
Industry : Health Technology . Medical Specialties
Position Proposed: BUY
Entry : NOW READY (0.8836-1.2428)
1st Partial Take Profit: 1.5501 (AUG 2021-OCT 2021)
2nd Partial Take Profit: 2.0080 (Early Jan 2022-March 2022)
Expected Take Profit: 3.9000 (July 2022- OCT 2022)
STOP LOSS: 0.4617
Technical Analysis:
1. Large Inverted Head & Shoulders (Formed and now forming retracement)
2. Smaller Inverted Head & Shoulders (Forming)
3. Double Bottom Formation Forming (First Head - 0.4700, Second Head-0.6525)
4. Fibonacci Retracement at 0.786, Expansion Fibonacci Retracement indicates a potential BUY Opportunity
5. Small Flag Pattern Forming Now (4th Jan - 3rd May)
6. Safest Take Profit will land equivalent to the Flagpole length and level 1 of Fibonacci Expansion Grey Zone.
7. The Market should potentially reach our Expected Take Profit will also be at EMA 60
CFMS
My recommended portfolio for the next trading week,25-29 Jan 20First of all, I thanks all those who supported me in last week,specially Muhannadmawed, gv1990, TradingView,and John71505.
1-ADTX @ 3.60
2-AKRO @ 31.06
3-AMC @ 3.51
4-AMD @ 92.79
5-BYND @ 140.70
6-CFMS @ 1.40
7- CRM @ 225.77
8-EYES @ 1.94
9- FUBO @ 37.72
10- GNUS @ 1.57
11- JE @ 6.85
12- KIRK @ 28.07
13- KODK @ 9.46
14- LYL @ 2.71
15- MTC @ 2.44
16- NIO @ 61.95
17- OPTT@ 5.60
18- PAYS@ 5
19-PLTR @32.58
20- SOLO@ 8.16
21-SPCE @ 34.58
22-SYN @ 0.9116
23- THMO @ 2.65
24- TSLA @ 846.64
25- WKHS @ 23.51
This is just my technical view, neither a fundamental comment,nor a recommendation to trade..!
Please review my track record and calculate the odds of success for yourself..!
Don't forget to like, comment, and Follow to encourage me to continue this.
I would appreciate if you share my analysis on your own social media.
You can send TradingView coins to support me publishing high quality ideas..!
Stay tuned great live stream and quality content videos coming soon..!
Wish you a profitable trading week
Moshkelgosha
Do Old day tricks still work..?Have you ever heard of Nicholas Darvas???
Nicolas Darvas was a dancer, self-taught investor and author. He is best known for his book, "How I Made $2,000,000 in the Stock Market." He wrote his book 60 years ago and his methodology still works!
Conformis is a crystal clear example, by looking at the previous time that 20 SMA crossed up 50 SMA you will find out that price in read 206% in 13weeks..!
In the next 12 weeks we will find out if history repeat itself or not???
And I will try to explain his updated method in a video in near future..!
I always try to present the charts in a simple comprehensive format to prevent any confusion.
This is just my technical view, neither a fundamental comment,nor a recommendation to trade..!
Don't forget to like, comment, and Follow to encourage me to continue this.
You can support my work by sending TradingView coins if you like them ( each coin 1 cent)
$CFMS Volume Light...Is This Topping?CFMS still within its "gap zone" from when it gapped down previously . However, the price continued higher today. But volume is a bit slower on Wednesday. Can this technically continue higher if volume continues to be this low compared to Tuesday?
"It emerged that the company entered into a lucrative agreement with Stryker Corporation. Stryker is one of the world’s foremost medical technology companies. According to the terms of the deal, Conformis is going to both sell and license its products to Stryker. Conformis is going to be paid $14 million by Stryker straightaway and stands to be paid $16 million more if certain targets are met. It is a significant deal and one that could be a key focus for the market." *
About CFMS
Conformis Inc is a US-based medical technology company. It uses iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped to fit each patient's anatomy. The company's iFit technology platform comprises three key elements which are iFit design, iFit printing, and iFit just-in-time delivery. It offers various partial and total knee replacement implants which include iTotal CR, iTotal PS, iDuo, and iUni. The company operates in the segment of knee replacement market. Its total revenue generated from the sale of its products to hospitals and other medical facilities. The majority of the company's revenue comes from the United States.
Quote Source: 3 Robinhood Penny Stocks To Watch In October
The Conformis Come-BackConformis Inc. (Nasdaq: CFMS) is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture & sell patient specific joint replacement implants. The implants are designed to fit each patient's unique anatomy.
CFMS stated in their previous ER (July 31, 2019), the company was updating their 2019 outlook to have "generally flat year-over-year product revenue growth for the full year 2019." The 'expected decrease in growth' was primarily due to denials in coverage from Aetna, the 3rd largest commercial payer. During the conference call, CFMS said they had "submitted its clinical and economic data to Aetna and understands that Aetna is currently reviewing its medical coverage policy." During the conference call, Conformis CEO suggested a potential update was coming this September from Aetna.
As we approach mid-month, price has held 50 retracement from the lower-high made on August 28, 2019 ($2.33 ). Conformis stated that the letter denying coverage from Aetna only referred to Conformis as a company, rather than a product denial per usual standards. If Aetna did make a mistake and is willing to cover the Conformis custom joint replacements, this could bring massive upside to the current stock price.I am forecasting a $5 PT (assuming CFMS gets Aetna coverage as they did with Cigna before).
Data from July 2019 10-K
Market Cap: $137.357 Million
Cash : $20.66 Million
Revenue (product and royalty): $19.593 Million
YoY Rev: +3%
52 Week High: $4.83
Ave Vol(10 Day): 628,900
Shares Outstanding: 68.68 Million
Shares Float: 50.01 Million
Technical's
As shown in the previous chart , CFMS is positioned for a breakout. Price has continued to hold the 50% retracement from the Aug. 28, 2019 high. Previous patterns from January 2019 show similar price movement (trend-line in blue), indicating a "new" uptrend in the making.
-Bullish Gartley in tact;
-Aligning Fib time-cycles;
-RSI approaching breakout level;
-Our proprietary indicator showing strong momentum going into tomorrow's trading session (Flips green = Bullish AF), Weekly flashing bullish signal.
Conclusion
Potential of medicare approval for total knee replacement at surgery centers in 2020 is a huge opportunity as baby boomer population grows. The Aetna reimbursement issue will pass (as Cigna did). The soon to be released total hip system is being undervalued by the market. I am forecasting a $5 PT foregoing CFMS getting Aetna coverage.
To read more of my analysis on CFMS visit our site, here . Please like and follow so I can continue finding awesome charts! Thanks in advance team d+)
Disclosure: I am long CFMS. This is not a note to buy or sell. Please do your homework before investing.
CFMS - On Target To Continue Bullish TrendConforMIS, Inc. operates as a holding company, which engages in the development, manufacture and sale of joint replacement implants. Its products include iTotal, iUni and iDuo and iJig Instrumentation. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.
SHORT INTEREST
4.8M 08/15/19
P/E Current
-2.87
P/E Ratio (with extraordinary items)
-4.22
Average Recommendation: OVERWEIGHT
Average Target Price: 4.00
CFMS - Earnings Report Coming, Downtrend Over?ConforMIS (CFMS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 31. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
(Source:https://finance.yahoo.com/news/conformis-cfms-may-report-negative-143202759.html?.tsrc=rss)
ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient's anatomy. The Company's iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient's knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.
SHORT INTEREST
4.12M 06/28/19
P/E Ratio (with extraordinary items)
-3.84
Analyst Price Prediction: $4.50
Average Recommendation: Overweight
